Bar-Ilan University

omniQ’ Announces the Election of Professor Mina Teicher to the Board of Directors

Retrieved on: 
Donnerstag, Dezember 22, 2022
Precision medicine, Bar-Ilan University, Australian Drug Evaluation Committee, RET, Executive Committee, Board of Governors of the International Atomic Energy Agency, Knowledge, Arab International Women's Forum, SALT, United States – Israel Binational Science Foundation, Ethics, Security, Artificial intelligence, Complex system, Machine learning, S-1 Executive Committee, Mathematics, Specialization, IWF, UNESCO, German, Management, Blockchain, Science

Professor Mina Teicher is a world known mathematician and the Chair of the largest brain research division at Bar-Ilan University and has directed the German “Emmy Noether Research Institute for Mathematics” at the Georg-August-Universität Göttingen since 1999.

Key Points: 
  • Professor Mina Teicher is a world known mathematician and the Chair of the largest brain research division at Bar-Ilan University and has directed the German “Emmy Noether Research Institute for Mathematics” at the Georg-August-Universität Göttingen since 1999.
  • Ms. Mina has also held many leadership roles in academia and science, including serving as chief scientist of the Israeli Ministry of Science and Technology, and chairing the Board of Governors of the United States – Israel Binational Science Foundation.
  • Shai Lustgarten, CEO commented “Mina brings a wealth of knowledge and experience to the board of Omniq having spent nearly 50 years embracing mathematics and technologies.
  • Professor Teicher was elected to the Board of Directors in the Company’s Shareholders Meeting replacing General (Ret) Itzhak Almog who did not seek reelection due to personal reasons.

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Retrieved on: 
Donnerstag, Dezember 15, 2022
PEA, Acquisition, Canadian Securities Exchange, MEAI, Depression, Gonda, Clinical trial, Pharmacology, Research, Outline, Mental health, FDA, Hebrew University of Jerusalem, Cocaine, AUD, Science, FSE, Bar-Ilan University, Central nervous system, University, Frankfurt Stock Exchange, CWY, IPO, CSE, Eleazar Sukenik, IP, Obesity, Patent, Development, Patient, Therapy, Pharmaceutical industry, Management, BIRAD

Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.
  • We believe our proprietary CMND-100, 5-methoxy-2-aminoindane (“MEAI”)- based treatment can help provide relief to millions around the world.
  • I joined Clearmind when the company was founded, after a thorough examination of the science and the psychedelic fields.
  • CEO of Clearmind Medicine Inc.
    Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Medigus: ScoutCam Announces Appointment of Yehu Ofer as Chief Executive Officer

Retrieved on: 
Mittwoch, Oktober 19, 2022
Transport, Robotics, VP, Israel Defense Forces, National, Program, King Fahd Security College, AI, CEO, Nasdaq, Aviation, Solution, CBM, Director, Condition, Elbit Systems, MBA, TASE, Private Securities Litigation Reform Act, Bar-Ilan University, GLOBE, Israeli Air Force, Maintenance, Ownership, Retirement, Growth, PDM, Technology, MDGS, University of Haifa, Board, Fourth Industrial Revolution, Digital, OTCQB, Marketing, SEC, IAF, Maintenance (technical), Economics, Industry

Mr. Ofer also managed Elbit System's aerospace division as VP of large-scale development programs and VP of the Brazil business unit.

Key Points: 
  • Mr. Ofer also managed Elbit System's aerospace division as VP of large-scale development programs and VP of the Brazil business unit.
  • In his last position at Elbit Systems, Mr. Ofer served as VP of Global Business Development, Marketing and Sales, a position he held since 2020.
  • Prof. Benad Goldwasser, Chairman of the Board of ScoutCam, said: The Board of Directors and I are delighted to welcome Yehu Ofer to ScoutCam.
  • Mr. Ofer will also serve as CEO of ScoutCam Ltd., a subsidiary of ScoutCam Inc.
    ScoutCam is pioneering the Predictive Maintenance and Condition Based Monitoring markets with its visualization and AI platform.

ScoutCam Announces Appointment of Yehu Ofer as Chief Executive Officer

Retrieved on: 
Dienstag, Oktober 18, 2022
Transport, Predictive maintenance, VP, Xi, Israel Defense Forces, National, Program, King Fahd Security College, AI, Legislation, CEO, Board of directors, Aviation, Solution, News, CBM, Pandemic, Condition, Elbit Systems, Oxide, MBA, Private Securities Litigation Reform Act, Software, Company, Marketing, Ix, Bar-Ilan University, GLOBE, Israeli Air Force, Maintenance, Retirement, Growth, PDM, Security (finance), Industry, Technology, University of Haifa, Board, Fourth Industrial Revolution, U.S. Securities and Exchange Commission, Terminology, OTCQB, Compliance, Algorithm, Sale, SEC, IAF, Coronavirus, Trademark dilution, Vii, COVID-19, Maintenance (technical), Risk management, Economics

OMER, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- ScoutCam Inc. (OTCQB: SCTC), a leading provider of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) solutions, today announced the appointment ofYehu Oferas chief executive officer, effective immediately.

Key Points: 
  • OMER, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- ScoutCam Inc. (OTCQB: SCTC), a leading provider of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) solutions, today announced the appointment ofYehu Oferas chief executive officer, effective immediately.
  • Mr. Ofer also managed Elbit System's aerospace division as VP of large-scale development programs and VP of the Brazil business unit.
  • Prof. Benad Goldwasser, Chairman of the Board of ScoutCam, said: "The Board of Directors and I are delighted to welcome Yehu Ofer to ScoutCam.
  • Mr. Ofer will also serve as CEO of ScoutCam Ltd., a subsidiary of the Company.

The Liu Shiming Art Foundation Honors First Georgia State University Scholarship Recipient

Retrieved on: 
Montag, Oktober 3, 2022
Student, Ernest, Bar-Ilan University, Time, Freedom, Nanyang Academy of Fine Arts, Maryland Institute College of Art, Bezalel Academy of Arts and Design, University, Western University, Exhibition, UCLA, Partnership, Georgia State University, Water, Columbia University, Sculpture, Creativity, Travel, William E. Macaulay Honors College, GSU, CUNY, American University, Fireworks, Interior design, Rutgers University, Art

ATLANTA, Oct. 3, 2022 /PRNewswire/ -- The Liu Shiming Art Foundation and Georgia State University held an event this Thursday to commemorate the foundation and university's partnership, as well as GSU's first-ever Liu Shiming scholarship recipient. The event was held at GSU's Ernest G. Welsh School of Art and Design gallery, where an exhibition of Liu Shiming's art was on display, entitled, "Cutting Through Mountains to Bring in Water".

Key Points: 
  • The Liu Shiming Art Foundation and Georgia State University held an event to mark the beginning of their partnership by honoring the university's first Liu Shiming Scholar.
  • ATLANTA, Oct. 3, 2022 /PRNewswire/ -- The Liu Shiming Art Foundation and Georgia State University held an event this Thursday to commemorate the foundation and university's partnership, as well as GSU's first-ever Liu Shiming scholarship recipient.
  • Among the works of the late Chinese artist Liu Shiming, GSU and the foundation celebrated the scholarship recipient Leslie Drennan an Atlanta-based graduate student at the Ernest G. Welch School of Art and Design specializing in woodworking and sculpture.
  • The Liu Shiming Art Foundation is expanding its programs across the world to preserve the works of Liu Shiming and to support students of the arts with scholarships, grants, and exchange programs.

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Retrieved on: 
Montag, Oktober 3, 2022
Terminology, Skin, GLOBE, Doctor of Philosophy, NASDAQ, Sol–gel process, History, Management, SEC, Dermatology, Technology, Ix, Business development, Research, Industry, Private Securities Litigation Reform Act, NESS, University of Haifa, COVID-19, Annual report, Growth, Rosacea, Coronavirus, Accounting, Partnership, U.S. Securities and Exchange Commission, Acne, Bar-Ilan University, Psoriasis, Security (finance), Patient, Acquisition, Forward-looking statement, Retirement, Risk, Intellectual property, Vii, Marketing, Company, Pharmaceutical industry, Galderma, Economics

NESS ZIONA,Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.(NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development.

Key Points: 
  • NESS ZIONA,Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.(NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development.
  • In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Companys approved products in ex-US territories.
  • We are very pleased to have Michael join the Company as we expand our business development efforts, stated Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel.
  • Previously, Mr. Glezin was a Senior Business Development Executive at Dexcel Pharma, based in Or Akiva, Israel.

Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute

Retrieved on: 
Montag, September 19, 2022
Wolf Prize, Bioinformatics, Therapy, Safety, Molecular biology, Melanoma, MD, RNA transfection, Center, Faculty of Pharmacy, University of Lisbon, University, University of Erlangen–Nuremberg, Hebrew language, HCRI, Biochemistry, Hadassah Medical Center, Immunotherapy, Neoplasm, Cancer, Physician, Cancer epigenetics, Free University of Brussels (1834–1969), Goal, Biocomputing, Acute myeloid leukemia, Uveal melanoma, Centre for Genomic Regulation, Bar-Ilan University, RNA, Research, RNA splicing, Immune system, Pharmaceutical industry, Vaccine, Dietary supplement, Merck, Biobank

JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Key Points: 
  • JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.
  • While RNA-based therapies, namely mRNA vaccines, shined during the pandemic and saved millions of lives, they have yet to be successfully tested in cancer therapies.
  • About the Hadassah Cancer Research Institute:
    Hadassah Cancer Research Institute (HCRI) is a translational research arm of Hadassah Medical Organization and Sharett Cancer Center in Jerusalem.
  • For additional information on the Hadassah Cancer Research Institute and CanceRNA, contact:

IM Cannabis Welcomes Two New Members to its Board of Directors

Retrieved on: 
Dienstag, September 13, 2022
CFO, Advertising, Partner, Sale, Ramot at Tel Aviv University, Quality control, Organization, Cannabis, Company, Growth, Economics, Pharmacy, Patient, Bar-Ilan University, CEO, CSE, MBA, Solution, International Narcotics Control Board, Leadership, Ecosystem, The Company, NASDAQ, Collection, Board, University of Washington, Marketing, University, Metal, LIV, Drug, Management, IMC

TORONTO and GLIL YAM, Israel, Sept. 13, 2022 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, is pleased to announce that Einat Zakariya and Moti Marcus have been appointed to the Company's board of directors (the "Board"). Einat Zakariya and Moti Marcus will replace current board directors Vivian Bercovici and Haleli Barath, who have resigned from the Board to pursue other opportunities.

Key Points: 
  • Einat Zakariya and Moti Marcus will replace current board directors Vivian Bercovici and Haleli Barath, who have resigned from the Board to pursue other opportunities.
  • "We are delighted to welcome Einat Zakariya and Moti Marcus to our IMC family," said Oren Shuster, Chief Executive Officer of IM Cannabis.
  • IM Cannabis (NASDAQ: IMCC) (CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers.
  • In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it also distributes cannabis to pharmacies to medical cannabis patients.

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment

Retrieved on: 
Mittwoch, August 24, 2022
Hebrew University of Jerusalem, Eleazar Sukenik, CSE, Research, MEAI, FSE, RATS, Addiction, Animal, Bar-Ilan University, GLOBE, Crave, Therapy, Gonda, OTC Markets Group, Acquisition, Cocaine, Pharmaceutical industry, Drug

VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

Key Points: 
  • VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
  • "We are very excited by these new results which further strengthen our previous results indicating the potential of our proprietary MEAI to treat cocaine addiction, said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer.
  • As cocaine is extremely addictive and there is currently no dedicated treatment, I believe Clearmind is leading the way in this field.
  • This research demonstrates again MEAIs unique ability to treat cocaine addiction and its potential to become the first dedicated cocaine addiction treatment.

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Retrieved on: 
Mittwoch, August 24, 2022
CBD, Hebrew University of Jerusalem, THC, Eleazar Sukenik, CSE, Pain, OTC, Research, Central nervous system, MEAI, Risk, Status epilepticus, FSE, Tourette syndrome, SEC, Agitation, U.S. Securities and Exchange Commission, Addiction, Alzheimer's disease, Bar-Ilan University, Animal, GLOBE, Intention, Crave, TEL, Nasdaq, Company, Therapy, Cocaine, Gonda, Clinical trial, Annual report, Private Securities Litigation Reform Act, Acquisition, Autism, Rat, Pharmaceutical industry

TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).

Key Points: 
  • "We are excited about these recent results in light of the potential synergistic effect between SciSparcs CannAmide and Clearminds MEAI, as previously demonstrated.
  • These results continue to indicate that we may have a targeted treatment for cocaine addiction within our reach, commented Oz Adler, SciSparc's Chief Executive Officer.
  • "These results reinforce our decision to enter a collaboration between the two companies."
  • Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University.